2019 Annual Business Report

A specialty
vaccine company

img-small

CEO statement

“2019 has been an exceptional year for Valneva.”

Thomas Lingelbach President & CEO of Valneva

Product
sales 2019

129.5m
Our employees

Our employees

Valneva’s success stems from the dedication and expertise of about 500 employees covering the whole value chain, from R&D to commercialization.

2019  Highlights

2019 Highlights

In 2019, Valneva achieved several major milestones, further enhancing its unique value proposition.

Our strategy

Our strategy

Valneva aims to become the leading specialty vaccine company.

Frédéric Jacotot General Counsel and Corporate Secretary

Committed to the best Corporate Governance Practice Our Corporate Governance Approach

Our Corporate Governance Approach

Our commitment to Corporate Governance underpins the trust that our investors, employees and institutions have placed in us.

Corporate Social Responsibility

Corporate Social Responsibility

Valneva has defined long-term responsible business commitments, which reflect global health needs and sit across four key focus areas. Our four pillars are the foundation for our Corporate Social Responsibility approach.